Clinical Trials Browser

Recruiting × Recurrence × 90 days × Clear all

NCT06634589 2026-03-18

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

Phase 1/2 Recruiting

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT06725173 2026-03-18

Detailed Phenotypic and Genotype Study to Correlate RB1 Mutations Relating to Primary Ocular Tumors and Secondary Extra-ocular Metastasis.

Other solid neoplasm

Recurrence, Retinoblastoma

NCT07209449 2026-03-18

A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer

Phase 2 Recruiting

Recurrence, Endometrial Neoplasms

NCT07480213 2026-03-18

DART-NK-SCLC

Phase 1/2 Recruiting

Recurrence, Small Cell Lung Carcinoma

NCT07480954 2026-03-18

DUAL-OV-CAR-NK

Phase 1/2 Recruiting

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Recurrence

NCT06161519 2026-03-17

PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications

Phase 1/2 Recruiting

Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Recurrence

NCT06189391 2026-03-17

MK-1045-001

Phase 1 Recruiting

Recurrence, Lymphoma, B-Cell

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT07156565 2026-03-17

ATLAS

Phase 1 Recruiting

Recurrence, Sarcoma

NCT07164560 2026-03-17

Exploratory Study of Umbilical Cord Blood-Derived CAR-NK Cell Therapy Targeting TRBC1/2 for Relapsed/Refractory T-Cell Lymphoma

Phase 1 Recruiting

Recurrence, Lymphoma, T-Cell, Peripheral

NCT07221253 2026-03-17

AB02

Phase 3 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT07137494 2026-03-16

A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)

Phase 1 Recruiting

Lymphoma, Recurrence

NCT07297979 2026-03-16

Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS)

Phase 1 Recruiting

Recurrence, Sarcoma, Ewing

NCT07472972 2026-03-16

Dynamic Individualized Risk Profiling of Patients With Relapsed/Refractory Lymphoid Malignancies and CD19-CAR T Cell Therapy (INTeRCePT 2.0)

Lymphoma, Recurrence

NCT03460977 2026-03-13

A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma

Phase 1 Recruiting

LymphoidThoracic

Lymphoma, Follicular, Recurrence, Small Cell Lung Carcinoma

NCT05588141 2026-03-13

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Phase 1/2 Recruiting

Brain Neoplasms, Glioma, Neoplasms, Recurrence

NCT05652335 2026-03-13

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis

Phase 1 Recruiting

Amyloidosis, Multiple Myeloma, Recurrence

NCT06604715 2026-03-13

A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05292664 2026-03-12

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Phase 1 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Biphenotypic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06832865 2026-03-12

ELISA in Relapsed/Refractory MM

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05519085 2026-03-11

SUCCESSOR-1

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05748197 2026-03-10

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

Phase 1 Recruiting

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT06459024 2026-03-10

IMPACT STREAM

Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT07257419 2026-03-10

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07460362 2026-03-10

Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2 Recruiting

Recurrence, Lymphoma, Mantle-Cell

NCT05669846 2026-03-09

Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung, Recurrence

NCT06704659 2026-03-09

RAY-no-BAN

Phase NA Recruiting

Breast Neoplasms, Recurrence

NCT04521231 2026-03-06

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05533775 2026-03-06

iMATRIX GLO

Phase 1/2 Recruiting

Recurrence

NCT06149286 2026-03-06

OLYMPIA-5

Phase 3 Recruiting

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT06375044 2026-03-06

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT05927571 2026-03-05

A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)

Phase 1 Recruiting

Multiple Myeloma, Recurrence

NCT07280013 2026-03-05

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Phase 1 Recruiting

Bites and Stings, Multiple Myeloma, Recurrence

NCT06321484 2026-03-04

Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer

Phase 1 Recruiting

Ovarian Neoplasms, Recurrence

NCT06551324 2026-03-04

MEVPRO-1

Phase 3 Recruiting

Prostatic Neoplasms, Recurrence

NCT06868433 2026-03-04

TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer

Phase 1 Recruiting

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Recurrence

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05681195 2026-03-03

Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas

Phase 2 Recruiting

Neoplasms, Recurrence

NCT07166094 2026-03-03

RAINFOL-03

Phase 3 Recruiting

Recurrence, Endometrial Neoplasms

NCT06173518 2026-03-02

A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

Phase 1 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Recurrence, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06760637 2026-03-02

FourLight-3

Phase 3 Recruiting

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06806033 2026-03-02

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT02974647 2026-02-27

Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma

Phase 2 Recruiting

Lymphoma, Recurrence

NCT07138209 2026-02-27

A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT02926690 2026-02-25

Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer

Phase 1 Recruiting

Breast Neoplasms, Recurrence, Triple Negative Breast Neoplasms

NCT05826535 2026-02-24

Study of LYL314 in Aggressive Large B-Cell Lymphoma

Phase 1/2 Recruiting

Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Disease Attributes

NCT07116616 2026-02-24

A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT07123454 2026-02-24

Lumi-NHL

Phase 1/2 Recruiting

Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, B-Cell

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence